APAC Injectable Drug Delivery Market

The Asia Pacific injectable drug delivery market is projected to reach USD 282.22 billion by 2031 from USD 176.96 billion in 2026, growing at a CAGR of 9.8% during the forecast period.

The growth of the Asia Pacific injectable drug delivery market is driven by the increasing prevalence of chronic diseases, such as cancer, diabetes, autoimmune disorders, and infectious conditions. This drives demand for biologics, biosimilars, gene therapies, and long-acting injectables, thereby strengthening the need for advanced delivery solutions. The shift toward personalized medicine, controlled-release systems, and self-administration therapies is creating significant opportunities for innovation in prefilled syringes, autoinjectors, pen injectors, wearable on-body devices, and smart connected platforms. The growing adoption of digital health tools, remote patient monitoring, eHealth integration, and EU-supported data-driven care models is further expanding the scope of injectable delivery technologies. Evolving EU regulatory frameworks, the expansion of regional biologics manufacturing capacity, growth in home-care treatment models, and increasing collaborations between device manufacturers, biopharma companies, and CDMOs are accelerating the strong expansion of the Asia Pacific injectable drug delivery market.

To know about the assumptions considered for the study download the pdf brochure

The prominent Asia Pacific injectable drug delivery device manufacturers are BD (US), Terumo Corporation (Japan), Nipro (Japan), Hindustan Syringes & Medical Devices Ltd (India), and B. Braun SE (Germany), among others. Asia Pacific injectable drug delivery formulation manufacturers are Pfizer Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Novo Nordisk A/S (Denmark), and Novartis AG (Switzerland), among others. These players have adopted organic and inorganic growth strategies, such as product development, partnerships, and collaborations.

 In June 2025, Ypsomed AG (Switzerland) opened its first dedicated production site in China. This will help produce 100 million injection devices per year in China.

In October 2024, BD (US) collaborated with Ypsomed to advance self-injection solutions for high-viscosity biologic drugs, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format.

Asia Pacific Injectable Drug Delivery Device Manufacturers

BD is a global medical technology leader with a broad product offering that includes medical devices, instruments, and systems, and reagents across 190+ countries. The company focuses on three core business segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical includes Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring. Its Pharmaceutical Systems unit supplies needles, syringes, and IV catheters. The Life Sciences segment includes Integrated Diagnostic Solutions and Biosciences. The Interventional segment encompasses Surgery, Peripheral Intervention, and Urology & Critical Care, focusing on minimally invasive and critical care devices. It has an international presence with subsidiary operations in the US, Canada, and Germany.

Terumo Corporation is a medical device entity that offers development and commercializes products worldwide, including syringes, needles, catheters, and blood collection systems. The company has three main business groups - Blood and Cell Technologies, Cardiac & Vascular, and Medical Care Solutions. The Hospital Care Products unit provides a range of products for drug delivery, including insulin and allergy syringes, winged needle sets, veterinary syringes, infusion and syringe pumps, and infusion sets. Meanwhile, its Life Care Solutions unit manufactures insulin patch pumps. The company operates in over 160 countries, with over 50,000 product offerings for doctors, hospitals, clinics, academic institutions, pharmaceutical, and biotechnology companies.

Asia Pacific injectable drug delivery Formulation Manufacturers

Pfizer Inc. is an international biopharmaceutical firm engaged in developing, making, and selling biopharmaceuticals, vaccines, and consumer healthcare products. The company operates through three main business segments: Biopharma, Pfizer CentreOne, and Pfizer Ignite. Pfizer CentreOne acts as the contract manufacturing organization for specialty APIs, as Pfizer Ignite fosters biotech partnerships with R&D capabilities that align with Pfizer’s scientific priorities. The Biopharma business unit offers core therapeutics and vaccines. In 2024, the company was divided into Pfizer Oncology, Pfizer US Commercial, and Pfizer International Commercial divisions, with sterile injectables made available under the International Commercial subsegment. Pfizer maintains a global footprint with operations in more than 40 countries, and its production facilities are strategically located within prominent regions.

Sanofi is a global biopharmaceutical company that focuses on researching, developing, manufacturing, and marketing a large portfolio of prescription and vaccine products and therapies for various significant medical needs, including immunology, oncology, rare diseases, neurology, diabetes, cardiovascular disease, and infectious diseases. Its business operations are categorized into two main sectors: Pharmaceuticals and Vaccines. A strong pipeline and R&D efforts have been implemented and continue to support these two sectors, with a strong focus on biologics, immunotherapy, and next-generation platforms. As a constituent within the largest vaccine makers worldwide via Sanofi Vaccines, it supplies solutions for pediatric, travel, endemic, and seasonal immunizations.

Market Ranking (Device Manufacturers)

The top five Asia Pacific injectable drug delivery device companies are BD (US), Terumo Corporation (Japan), Nipro (Japan), Hindustan Syringes & Medical Devices Ltd (India), and B. Braun SE (Germany). BD is increasing its leadership in injectable drug delivery with a complete portfolio of prefillable injection systems, safety-engineered injection devices, and systems suitable for biologic drugs and high-viscosity drugs, and Terumo Corporation is increasing its market share with advanced syringe systems, needles, infusion devices, and drug delivery systems focused on accuracy and patient safety. Nipro is increasing its market share in injectable delivery systems with high-quality syringe systems, needles, and medical-grade components suitable for large-scale usage in hospitals and pharmaceutical companies. Hindustan Syringes & Medical Devices Ltd is involved in emerging markets with mass production systems available for auto-disable injection systems, disposable injection systems, and needle systems suitable for large-scale vaccination and therapy programs. B. Braun SE is offering advanced infusion therapy systems, safety syringe systems, and combination medication systems developed for high reliability in hospitals and clinics.

Market Ranking (Formulation Manufacturers)

The top injectable drug delivery formulation companies in the Asia Pacific are Pfizer Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Novo Nordisk A/S (Denmark), and Novartis AG (Switzerland). The injectable footprint of Pfizer Inc. is being enhanced by a comprehensive portfolio of sterile injectables, biotherapeutics, and oncology therapies, which is supported by a global network of high-capacity, dependable manufacturing facilities to ensure a reliable supply. Sanofi supplements its leadership with a diversified portfolio of injectable biologics for immunology, diabetes, oncology, and vaccine therapeutic areas, supported by strong research and development, as well as advanced production capabilities in biologics. F. Hoffmann-La Roche Ltd goes further in the dominant competitive position of injectable biologics in oncology and immunology because of its unparalleled expertise in monoclonal antibodies and extensive large-scale biologics facilities. Novo Nordisk A/S has enhanced its presence in injectables, offering therapies for diabetes, obesity, and rare diseases, alongside world-class facilities and biologics and injectable manufacturing infrastructure. Novartis AG is expanding in injectable oncology and specialty biologics with special production facilities and state-of-the-art formulation technologies for complex therapies.

Related Reports:

APAC Injectable Drug Delivery Market by Product (Device, Autoinjectors, Formulation, Suspensions, Nanoparticles), Site of Administration (Dermal, Organ), Formulation Packaging (Ampoules, Vials), Usage Pattern (Curative, Immunization) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com